Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Verrica Pharmaceuticals Inc (VRCA)

Verrica Pharmaceuticals Inc (VRCA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,278
  • Shares Outstanding, K 45,601
  • Annual Sales, $ 5,120 K
  • Annual Income, $ -67,000 K
  • EBIT $ -78 M
  • EBITDA $ -77 M
  • 60-Month Beta 1.40
  • Price/Sales 6.26
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.61
  • Most Recent Earnings $-0.49 on 11/04/24
  • Next Earnings Date 11/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 526.52% ( +3.51%)
  • Historical Volatility 95.85%
  • IV Percentile 91%
  • IV Rank 52.86%
  • IV High 971.97% on 11/13/24
  • IV Low 27.00% on 09/19/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 101
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 1,302
  • Open Int (30-Day) 1,311

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.23
  • Number of Estimates 1
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +52.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6109 +6.19%
on 12/19/24
1.3600 -52.30%
on 11/27/24
-0.4613 (-41.56%)
since 11/26/24
3-Month
0.6109 +6.19%
on 12/19/24
1.7494 -62.92%
on 09/27/24
-1.0313 (-61.39%)
since 09/26/24
52-Week
0.6109 +6.19%
on 12/19/24
11.4100 -94.31%
on 05/14/24
-5.8513 (-90.02%)
since 12/26/23

Most Recent Stories

More News
Verrica Provides Business and Operational Update

VRCA : 0.6487 (-5.42%)
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

VRCA : 0.6487 (-5.42%)
Verrica Pharmaceuticals Announces NDA Submission for TO-208 for Molluscum Contagiosum Treatment in Japan

Verrica Pharmaceuticals announced Torii's NDA submission for TO-208 to treat molluscum contagiosum in Japan.Quiver AI SummaryVerrica Pharmaceuticals Inc. announced that its partner Torii Pharmaceutical...

VRCA : 0.6487 (-5.42%)
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

VRCA : 0.6487 (-5.42%)
Verrica Announces Pricing of $42.0 Million Public Offering

VRCA : 0.6487 (-5.42%)
Verrica Pharmaceuticals Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants

Verrica Pharmaceuticals plans an underwritten public offering of common stock and warrants, subject to market conditions.Quiver AI SummaryVerrica Pharmaceuticals Inc. announced its plans to conduct an...

VRCA : 0.6487 (-5.42%)
Verrica Announces Proposed Public Offering

VRCA : 0.6487 (-5.42%)
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

VRCA : 0.6487 (-5.42%)
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

VRCA : 0.6487 (-5.42%)
Why Shares of Verrica Pharmaceuticals Are Plummeting on Monday

The company's shares dropped because it will require financing to help launch its first marketed product.

VRCA : 0.6487 (-5.42%)

Business Summary

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company. It develops and manufactures pharmaceutical products for the treatment of skin diseases such as molluscum contagiosum and dermatology. Verrica Pharmaceuticals, Inc. is based in PA, United States.

See More

Key Turning Points

3rd Resistance Point 0.7905
2nd Resistance Point 0.7506
1st Resistance Point 0.6997
Last Price 0.6487
1st Support Level 0.6089
2nd Support Level 0.5690
3rd Support Level 0.5181

See More

52-Week High 11.4100
Fibonacci 61.8% 7.2847
Fibonacci 50% 6.0104
Fibonacci 38.2% 4.7362
Last Price 0.6487
52-Week Low 0.6109

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar